Adaptlate - a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+/Her2- early breast cancer
Abemaciclib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Adaptlate - a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+/Her2- early breast cancer ### Output: Abemaciclib